Loqtorzi (disitamab vedotin plus toripalimab-tpzi) demonstrated a statistically vital enchancment in survival in contrast with standard-of-care chemotherapy as a frontline therapy for...
Including Tecentriq to chemo resulted in survival outcomes similar to placebo plus chemo in sufferers with superior or recurrent endometrial most cancers,...
The addition of the oral AKT inhibitor Truqap (capivasertib) to Zytiga (abiraterone acetate), prednisone and androgen deprivation remedy (ADT) prolonged investigator-assessed radiographic...
Amongst sufferers with high-risk, HER2-positive main breast most cancers with residual invasive illness following neoadjuvant remedy, remedy with Enhertu (fam-trastuzumab deruxtecan-nxki; T-DXd)...
Amongst sufferers domestically superior, unresectable, stage 3 non-small cell lengthy most cancers (NSCLC) that has not progressed after platinum-based concurrent chemoradiation (cCRT),...
